Please assess the completion status of the following clinical trial:

Trial Title: Propranolol in Capillary Hemangiomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant aged less than 4 months~* Infant with one or more hemangiomas sized more than 1 cm diameter~* Infant not threatening for vital or functional structure and for which no treatment would be proposed~* Informed consent~* Patient with social insurance.~Exclusion Criteria:~* Alarming hemangioma (s) (complicated forms or localization at risk)~* Cardiac pathology (cardiac malformation, heart failure, cardiac arrhythmias, pulmonary hypertension)~* Asthma~* Bronchopulmonary dysplasia~* Bronchiolitis~* Raynaud syndrome~* Phéochromocytoma~* Development of serious form of hemangioma (bleeding, necrosis, ulceration, infection, respiratory distress) requiring standard treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): 30-days placebo treatment
- 1 (Type: EXPERIMENTAL): 30-days propranolol treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).